ECS06
SUBSTITUTION REGENERATIVE THERAPIES FOR LIMBAL, ENDOTHELIAL, AND RETINAL DYSFUNCTION
M. V. Tsurkan1,*
1TissueGUARD GmbH, Dresden, Germany
TissueGUARD GmbH is a privately-funded biotechnology company dedicated to developing and producing advanced hydrogel materials as medical devices. Our mission is to create innovative biotechnology solutions for tissue and organoid engineering as regenerative therapeutics.
At TissueGUARD, we have developed proprietary hydrogel materials that are fully defined, sacrificially degradable, and capable of supporting the growth of almost any cell type. Our unique technology allows for the on-demand removal of the device without harming the formed organoids or tissues, enabling the formation of physiological-sized, donor-like grafts. This scaffold-free approach simplifies tissue and organoid implantation, enhances therapeutic outcomes, prevents implantation-associated complications, and significantly reduces regulatory certification burdens in both the EU and the USA.
Our cutting-edge bioengineering capabilities have led to remarkable advancements in ocular regenerative approaches. Our technique enables the formation of corneal endothelium grafts with preformed Descemet-like membranes. It has also been shown to form retinal pigment epithelium (RPE) with preformed Bruch’s membrane. These pioneering tissue graft technologies have demonstrated potential in stabilizing surgical implantation and improving outcomes in ophthalmologic procedures. TissueGUARD’s technology not only addresses the critical shortage of donor tissues but also paves the way for comprehensive regenerative therapies for limbal, endothelial, and retinal dysfunctions.